RealFeedApp New verdict on Vyglxia expected in first quarter of next year
The FDA has accepted a revised application for Vyglxia, a drug previously rejected by the agency. An expert panel will review the findings, with a new decision expected in the first quarter of next year.
- Field
- drugs and trials
- What they did
- Biohaven has received permission from the FDA to review its application for Vyglxia again, after it was previously rejected.
- Why it matters
- This offers the developer a second chance to get regulatory approval for treating rare genetic disorders affecting the nervous system.
#fda#vyglxia#biohaven#rare disease#regulatory review
